Long-term safety of adalimumab in clinical trials in adult patients with Crohn's disease or ulcerative colitis.

Jean Frederic ColombelW J SandbornW ReinischL Peyrin-BirouletR PanaccioneP RutgeertsStephen HanauerS GhoshG Van AsscheA M RobinsonW LauJ-F MaaB HuangB PappalardoH Read

Published in: Alimentary pharmacology & therapeutics (2017)

Patients with moderately to severely active Crohn's disease or ulcerative colitis continued to experience acceptable safety with adalimumab, without new safety signals.

Keyphrases

ulcerative colitis
clinical trial
rheumatoid arthritis
juvenile idiopathic arthritis
study protocol
hidradenitis suppurativa